To further its mission to educate, lead, and serve, the American College of Toxicology is proud to offer a new eLearning Seminar focused on Specialty Oncology Biotherapeutics. These four modules are intended to present practical, real world nonclinical, regulatory, and in vivo study considerations for the development of specialty oncology biotherapeutics including cell therapies, complex protein biotherapeutics including immunomodulatory molecules, and oncolytic viruses.
Modules will be available for purchase as a discounted set of four modules only. Once the live module presentations conclude, registrants will have on-demand access to the modules for 30 days from the time each archive is first accessed. Each module is 90 minutes or fewer in duration.
All live module presentations are scheduled at 11:00 AM Eastern Time.
• Module 1: Recording Archive Available
Regulatory Considerations for Specialty Oncology Biotherapeutics
Module 1 Abstract
• Module 2: Recording Archive Available
Practical Nonclinical Considerations for Developing Autologous and Allogeneic Cell Therapies
Module 2 Abstract
• Module 3: Recording Archive Available
Part 1: Immune Assessment of Immunomodulatory Biotherapeutics
Module 3 Abstract
Part 2: Approaches to MABEL Starting Dose Selection
Sanela Bilic, Vanadro
Module 3 Abstract
• Module 4: Recording Archive Available
Case Studies for the Development of Specialty Biotherapeutics
Module 4 Abstract
Part 2: Michelle Coulson, Novartis
Module 4 Abstract
The Specialty Oncology Biotherapeutics eLearning seminar content will only be available until December 31, 2025.
As part of your registration, you will have unlimited access to either the individual module or set of modules recordings for 30 days. The 30-day access will begin when you access each individual module link. Certificates will be provided for each module. If you have any additional questions, please contact ACT Headquarters.
- Module 1: Regulatory Considerations for Specialty Oncology Biotherapeutics
- Module 2: Practical Nonclinical Considerations for Developing Autologous and Allogeneic Cell Therapies
- Module 3: (Part 1) Immune Assessment of Immunomodulatory Biotherapeutics and (Part 2) Approaches to MABEL Starting Dose Selection
- Module 4: Case Studies for the Development of Specialty Biotherapeutics
Registration Fees:
Seminar registration is restricted to single person use only. Please note that all eLearning sales are final. No cancelations or refunds will be allotted after payment is processed.
The Specialty Oncology Biotherapeutics Seminar content will only be available until December 31, 2025.
| Set/Modules 1–4 | |
| ACT Student/Postdoctoral Researcher Members | $125 |
| ACT Members | $225 |
| Nonmembers | $350 |
